## Arjune Sen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6677565/publications.pdf

Version: 2024-02-01

279798 214800 2,515 66 23 47 citations h-index g-index papers 72 72 72 3169 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Genomic analysis of "microphenotypes―in epilepsy. American Journal of Medical Genetics, Part A, 2022, 188, 138-146.	1.2	3
2	Why won't it stop? The dynamics of benzodiazepine resistance in status epilepticus. Nature Reviews Neurology, 2022, 18, 428-441.	10.1	31
3	Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 291-294.	1.9	34
4	Safety of transcranial direct current stimulation in healthy participants. Epilepsy and Behavior Reports, 2021, 15, 100414.	1.0	2
5	Evaluating risk to people with epilepsy during the COVID-19 pandemic: Preliminary findings from the COV-E study. Epilepsy and Behavior, 2021, 115, 107658.	1.7	37
6	Pathological brain ageing in epilepsy and dementia: two sides of the same coin?. Brain, 2021, 144, 9-11.	7.6	5
7	A survey of the European Reference Network EpiCARE on clinical practice for selected rare epilepsies. Epilepsia Open, 2021, 6, 160-170.	2.4	3
8	Distinguishing psychogenic nonepileptic, mixed, and epileptic seizures using systemic measures and reported experiences. Epilepsy and Behavior, 2021, 116, 107684.	1.7	4
9	An evaluation of the effectiveness of perampanel in people with epilepsy who have previously undergone resective surgery and/or implantation of a vagal nerve stimulator. Epilepsy and Behavior, 2021, 116, 107738.	1.7	3
10	Apathy in small vessel cerebrovascular disease is associated with deficits in effort-based decision making. Brain, 2021, 144, 1247-1262.	7.6	25
11	Amyloid- $\hat{l}^2$ : a potential link between epilepsy and cognitive decline. Nature Reviews Neurology, 2021, 17, 469-485.	10.1	60
12	An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study. Trials, 2021, 22, 508.	1.6	20
13	The impact of COVID-19 on epilepsy care: Perspectives from UK healthcare workers. Epilepsy and Behavior Reports, 2021, 16, 100487.	1.0	0
14	Impact of the COVID-19 pandemic on people with epilepsy: Findings from the Brazilian arm of the COV-E study. Epilepsy and Behavior, 2021, 123, 108261.	1.7	8
15	Epilepsy and psychogenic non-epileptic seizures in forcibly displaced people: A scoping review. Seizure: the Journal of the British Epilepsy Association, 2021, 92, 128-148.	2.0	6
16	Optimising epilepsy care throughout the Afghan refugee crisis. Lancet, The, 2021, 398, 1563.	13.7	2
17	100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care â€" Preliminary Report. New England Journal of Medicine, 2021, 385, 1868-1880.	27.0	352
18	Vagus nerve stimulation therapy in people with drug-resistant epilepsy (CORE-VNS): rationale and design of a real-world post-market comprehensive outcomes registry. BMJ Neurology Open, 2021, 3, e000218.	1.6	2

#	Article	IF	CITATIONS
19	A pragmatic approach to intravenous anaesthetics and electroencephalographic endpoints for the treatment of refractory and super-refractory status epilepticus in critical care. Seizure: the Journal of the British Epilepsy Association, 2020, 75, 153-164.	2.0	22
20	The transition to status epilepticus: how the brain meets the demands of perpetual seizure activity. Seizure: the Journal of the British Epilepsy Association, 2020, 75, 137-144.	2.0	7
21	New-onset super refractory status epilepticus: A case-series. Seizure: the Journal of the British Epilepsy Association, 2020, 75, 174-184.	2.0	17
22	Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review. Epilepsy and Behavior, 2020, 103, 106861.	1.7	12
23	Executive summary and recommendations. Epilepsy and Behavior, 2020, 103, 106650.	1.7	1
24	What is status epilepticus and what do we know about its epidemiology?. Seizure: the Journal of the British Epilepsy Association, 2020, 75, 131-136.	2.0	26
25	Status epilepticus special edition. Seizure: the Journal of the British Epilepsy Association, 2020, 75, 129-130.	2.0	0
26	Development and validation of a predictive model of drug-resistant genetic generalized epilepsy. Neurology, 2020, 95, e2150-e2160.	1.1	22
27	Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 9318.	4.1	54
28	Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms. Brain, 2020, 143, 1731-1745.	7.6	74
29	Epilepsy in older people. Lancet, The, 2020, 395, 735-748.	13.7	170
30	Very late-onset mitochondrial cytopathy featuring epilepsia partialis continua and bilateral deafness: A case report. Seizure: the Journal of the British Epilepsy Association, 2020, 76, 153-155.	2.0	2
31	Binding deficits in visual shortâ€ŧerm memory in patients with temporal lobe lobectomy. Hippocampus, 2019, 29, 63-67.	1.9	26
32	Hippocampal epileptogenesis in autoimmune encephalitis. Annals of Clinical and Translational Neurology, 2019, 6, 2261-2269.	3.7	20
33	Perampanel for the treatment of epilepsy; Longitudinal actuarial analysis and dose responses based on monthly outcomes. Seizure: the Journal of the British Epilepsy Association, 2019, 69, 125-132.	2.0	10
34	An evaluation of the psychosocial impact of epilepsy on marriage in the United Kingdom. Epilepsy and Behavior, 2019, 94, 204-208.	1.7	6
35	Galvanic Skin Response (GSR)/Electrodermal/Skin Conductance Biofeedback on Epilepsy: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2019, 10, 377.	2.4	44
36	High glucose concentrations mask cellular phenotypes in a stem cell model of tuberous sclerosis complex. Epilepsy and Behavior, 2019, 101, 106581.	1.7	3

#	Article	IF	CITATIONS
37	Cognition and dementia in older patients with epilepsy. Brain, 2018, 141, 1592-1608.	7.6	177
38	A clinical-grade gene therapy vector for pharmacoresistant epilepsy successfully overexpresses NPY in a human neuronal cell line. Seizure: the Journal of the British Epilepsy Association, 2018, 55, 25-29.	2.0	8
39	Development of EpiRisk: An online clinical tool for estimating the risk of major congenital malformations in pregnant women treated for epilepsy. Epilepsia Open, 2018, 3, 281-285.	2.4	0
40	A neurological letter from Zimbabwe. Practical Neurology, 2018, 18, 255-257.	1.1	0
41	Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain, 2018, 141, 2263-2271.	7.6	100
42	New regulations to cut valproate-exposed pregnancies. Lancet, The, 2018, 392, 458-460.	13.7	6
43	Reply: Late onset epilepsy and Alzheimer's disease: exploring the dual pathogenic role of amyloid-β. Brain, 2018, 141, e61-e61.	7.6	2
44	The phenotype of bilateral hippocampal sclerosis and its management in "real life―clinical settings. Epilepsia, 2018, 59, 1410-1420.	5.1	6
45	Current practice and recommendations in UK epilepsy monitoring units. Report of a national survey and workshop. Seizure: the Journal of the British Epilepsy Association, 2017, 50, 92-98.	2.0	29
46	Morvan just a syndrome…!. Lancet, The, 2017, 389, 1368.	13.7	2
47	A point mutation in the ion conduction pore of AMPA receptor GRIA3 causes dramatically perturbed sleep patterns as well as intellectual disability. Human Molecular Genetics, 2017, 26, 3869-3882.	2.9	35
48	Hippocampal MRS and subfield volumetry at 7T detects dysfunction not specific to seizure focus. Scientific Reports, 2017, 7, 16138.	3.3	39
49	Comparing neurostimulation technologies in refractory focal-onset epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1174-1182.	1.9	55
50	The psychosocial impact of epilepsy on marriage: A narrative review. Epilepsy and Behavior, 2016, 63, 34-41.	1.7	22
51	YouTube as a potential learning tool to help distinguish tonic–clonic seizures from nonepileptic attacks. Epilepsy and Behavior, 2014, 37, 221-226.	1.7	17
52	Pathognomonic seizures in limbic encephalitis associated with anti-LGI1 antibodies. Lancet, The, 2014, 383, 2018.	13.7	25
53	Concise guide to the currently available drug options in epilepsy. The Prescriber, 2012, 23, 16-31.	0.3	0
54	Difficulty in walking 10 years after gastric surgery. European Journal of Gastroenterology and Hepatology, 2011, 23, 952-953.	1.6	6

#	Article	IF	Citations
55	The Potential Role of Cyclin-Dependent Kinase 5 in Focal Cortical Dysplasia. Developmental Neuroscience, 2008, 30, 96-104.	2.0	10
56	An Investigation of the Expression of G1-Phase Cell Cycle Proteins in Focal Cortical Dysplasia Type IIB. Journal of Neuropathology and Experimental Neurology, 2007, 66, 1045-1055.	1.7	11
57	Increased immunoreactivity of cdk5 activators in hippocampal sclerosis. NeuroReport, 2007, 18, 511-516.	1.2	12
58	Nova2 Interacts with a Cis-Acting Polymorphism to Influence the Proportions of Drug-Responsive Splice Variants of SCN1A. American Journal of Human Genetics, 2007, 80, 876-883.	6.2	104
59	Increased NKCC1 expression in refractory human epilepsy. Epilepsy Research, 2007, 74, 220-227.	1.6	59
60	Stertorous breathing is a reliably identified sign that helps in the differentiation of epileptic from psychogenic non-epileptic convulsions: An audit. Epilepsy Research, 2007, 77, 62-64.	1.6	43
61	Pathological Tau Tangles Localize to Focal Cortical Dysplasia in Older Patients. Epilepsia, 2007, 48, 1447-1454.	5.1	60
62	Deregulation of cdk5 in Hippocampal Sclerosis. Journal of Neuropathology and Experimental Neurology, 2006, 65, 55-66.	1.7	29
63	Hippocampal Malformations Do Not Necessarily Evolve into Hippocampal Sclerosis. Epilepsia, 2005, 46, 939-943.	5.1	14
64	Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 5507-5512.	7.1	321
65	The Psychosocial Burden of Cooley's Anemia in Affected Children and Their Parents. Annals of the New York Academy of Sciences, 1998, 850, 512-513.	3.8	15
66	Characteristics of surround inhibition in cat area 17. Experimental Brain Research, 1997, 116, 216-228.	1.5	195